Tempus AI (NASDAQ:TEM) Stock Price Down 0% After Insider Selling

Tempus AI, Inc. (NASDAQ:TEM)’s share price traded down 0% during mid-day trading on Thursday after an insider sold shares in the company. The stock traded as low as $47.12 and last traded at $48.02. 3,016,581 shares traded hands during trading, a decline of 40% from the average session volume of 5,007,310 shares. The stock had previously closed at $48.03.

Specifically, Director David R. Epstein sold 990 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $46.83, for a total transaction of $46,361.70. Following the sale, the director now directly owns 26,284 shares of the company’s stock, valued at $1,230,879.72. This represents a 3.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 13,135 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $45.98, for a total transaction of $603,947.30. Following the sale, the executive vice president now directly owns 154,171 shares in the company, valued at approximately $7,088,782.58. This trade represents a 7.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other news, CFO James William Rogers sold 23,030 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $45.97, for a total value of $1,058,689.10. Following the sale, the chief financial officer now directly owns 164,750 shares of the company’s stock, valued at approximately $7,573,557.50. This represents a 12.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. TD Cowen reissued a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Piper Sandler lowered their price target on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Morgan Stanley increased their price target on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Finally, Guggenheim reissued a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Trading Up 6.9 %

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business’s 50-day simple moving average is $56.35 and its 200 day simple moving average is $51.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. First Horizon Advisors Inc. bought a new position in Tempus AI during the third quarter valued at approximately $30,000. Operose Advisors LLC bought a new position in Tempus AI during the fourth quarter valued at approximately $25,000. Farther Finance Advisors LLC bought a new position in Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC grew its position in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new position in Tempus AI during the fourth quarter valued at approximately $49,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.